CAMP4 Therapeutics (NASDAQ:CAMP) Upgraded to "Strong-Buy" at Rodman & Renshaw

Key Points

• Rodman & Renshaw upgraded CAMP4 Therapeutics to a "strong-buy", while the broader analyst mix remains mixed (1 Strong Buy, 4 Buy, 1 Hold, 1 Sell) with a consensus rating of "Moderate Buy" and a consensus price target of $8.60.
• CAMP4 is trading near $4.52 (52‑week range $1.30–$7.75) but recently reported a large EPS miss (‑$0.87 vs. consensus ‑$0.31), posted extremely negative margins, and faces a full‑year EPS forecast of about ‑4.99.
• Multiple hedge funds — including Vivo Capital, Balyasny, Janus Henderson and others — have established or increased positions in CAMP, representing significant institutional interest.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) was upgraded by research analysts at Rodman & Renshaw to a "strong-buy" rating in a note issued to investors on Tuesday, Marketbeat Ratings reports.

CAMP has been the topic of several other research reports. Weiss Ratings restated a "sell (e+)" rating on shares of CAMP4 Therapeutics in a report on Monday, December 29th. Leerink Partners increased their price target on CAMP4 Therapeutics from $8.00 to $9.00 and gave the company an "outperform" rating in a report on Thursday, April 2nd. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of CAMP4 Therapeutics in a report on Friday, March 6th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $8.60.

CAMP4 Therapeutics Stock Performance

NASDAQ:CAMP opened at $4.52 on Tuesday. The stock's fifty day moving average is $4.59 and its 200 day moving average is $4.50. CAMP4 Therapeutics has a fifty-two week low of $1.30 and a fifty-two week high of $7.75. The firm has a market capitalization of $234.67 million, a PE ratio of -1.70 and a beta of 0.41.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last released its quarterly earnings results on Thursday, March 5th. The Wireless communications provider reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.56). CAMP4 Therapeutics had a negative net margin of 2,298.54% and a negative return on equity of 162.49%. The company had revenue of $0.35 million for the quarter. Equities analysts forecast that CAMP4 Therapeutics will post -4.99 EPS for the current year.

Hedge Funds Weigh In On CAMP4 Therapeutics

Several hedge funds have recently bought and sold shares of CAMP. Vivo Capital LLC bought a new position in CAMP4 Therapeutics in the 3rd quarter valued at $11,765,000. Balyasny Asset Management L.P. bought a new position in shares of CAMP4 Therapeutics during the 4th quarter worth $14,938,000. Janus Henderson Group PLC grew its position in shares of CAMP4 Therapeutics by 35.9% during the 4th quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider's stock worth $38,807,000 after buying an additional 1,666,666 shares in the last quarter. EcoR1 Capital LLC bought a new position in shares of CAMP4 Therapeutics during the 4th quarter worth $1,992,000. Finally, Geode Capital Management LLC grew its position in shares of CAMP4 Therapeutics by 457.0% during the 4th quarter. Geode Capital Management LLC now owns 336,293 shares of the Wireless communications provider's stock worth $2,063,000 after buying an additional 275,922 shares in the last quarter.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.